Successful wearable device selection for the evolving clinical trials landscape

September 8, 2020

Share this Article
Facebook
Twitter
Email
LinkedIn

There are a plethora of different devices available, ranging from commercially available actigraphy to specialized and medically approved devices. This article is designed to help sponsors consider which devices best meet their requirements when running a clinical trial.

An overview of the recent Executive Order on Critical Drugs Made in America

On August 6, 2020 the president of the United States signed an Executive Order (EO) on Ensuring Essential M...

The Move Toward Global Standards: Navigating New EAEU Guidelines

As the pandemic clearly revealed, there is an urgent need for a more cohesive, coordinated approach to stre...

Most Recent Articles

Threading the Eye of the Needle – FDA Sets Up a New Program for Importing Certain Products

Successful wearable device selection for the evolving clinical trials landscape

Previous Article

Next Article

Most Recent Articles

This blog focuses on unpacking the important points made in the companion Guidance for Industry – Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, and...

Despite the best efforts of the pandemic, the FDLI delayed but did not cancel its annual meeting for 2020 and hosted the event through a virtual platform. In this blog, I’ll walk through the...

No Content.

For any company on the receiving end of an FDA 483 or warning letter, standard operating procedures (SOPs) represent an opportunity to simultaneously achieve compliance and improve operational...

No Content.

On August 19, FDA published the final guidance Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers. You can find...

On August 6, 2020 the president of the United States signed an Executive Order (EO) on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States. The...

As the pandemic clearly revealed, there is an urgent need for a more cohesive, coordinated approach to streamline global regulatory guidelines to ensure patients have faster access to new and...

The regulatory pathway for COVID-19 drugs in China is governed by the Special Approval Program (SAP) which was introduced by National Medical Product Administration (NMPA) in 2005. SAP is...

Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...

Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and commercial success at the earliest stage. In that respect, regulatory considerations figure...

As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...

On March 27, 2020 the president of the United States signed into law the Coronavirus Aid, Relief and Economic Security (CARES) Act in response to the emerging pandemic (a copy of the public law...

On June 23, 2020 the European Medicines Agency (EMA) released a report on lessons learned from the presence of N-nitrosamine impurities in angiotensin II receptor blocker drugs. You can find a...

Decentralized clinical trials (DCT) had already begun to gain momentum, and the pandemic has dramatically accelerated their adoption. Enabling patients to participate in clinic trials from home is...